ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Pharmacology & Therapeutics
Volume 108, Issue 3, December 2005, Pages 320-333
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (216 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.pharmthera.2005.05.001    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2005 Elsevier Inc. All rights reserved.

Associate editor: B.L. Roth

5-HT6 receptors: a novel target for cognitive enhancement

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Ellen S. Mitchell and John F. NeumaierCorresponding Author Contact Information, E-mail The Corresponding Author

University of Washington, Box 359911, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104, USA


Available online 7 July 2005.

Abstract

Over the past decade, there has been increasing interest in the role of serotonin 6 (5-HT6) receptors in higher cognitive processes such as memory. Polymorphisms of the 5-HT6 receptor have been implicated in syndromes that affect cognition, such as schizophrenia and dementia. Manipulation of 5-HT6 receptor activity alters the transmission of several neurotransmitters important in memory: acetylcholine and glutamate, as well as dopamine, ã-aminobutyric acid (GABA), epinephrine (E), and norepinephrine (NE). Several 5-HT6 antagonists have been developed, advancing the understanding of the relationship between 5-HT6 blockade and memory consolidation in diverse learning paradigms. There is also evidence that 5-HT6 receptor activity affects anxiety behaviors and may be involved in the pathophysiology of schizophrenia. Several clinically useful atypical antipsychotics and antidepressants have 5-HT6 affinity, but recently developed selective 5-HT6 receptor antagonists may present attractive, new therapeutic options for several types of disease states.

Abbreviations: 5-HT, serotonin; 5,7-DHT, 5,7-dihydroxytryptamine; AO, antisense oligonucleotides; BDNF, brain derived growth factor; E, epinephrine; GABA, γ-aminobutyric acid; GAD, glutamic acid decarboxylase; GFP, green fluorescent protein; HSV, herpes simplex virus; LSD, lysergic acid diethylamide; MEST, maximal electroshock seizure threshold; NE, norepinephrine; NCAM, neural cell adhesion molecule; RT-PCR, reverse transcription polymerase chain reaction

Article Outline

1. 5-HT6 receptor neurobiology
1.1. Introduction
1.2. Genetics
1.3. Pharmacology
2. 5-HT6 interactions with other neurotransmitters
2.1. Acetylcholine
2.2. Dopamine
2.3. Excitatory amino acids
2.4. γ-Aminobutyric acid
2.5. Monoamines
3. Neurological disorders
3.1. Memory disorders/Alzheimer's disease
3.2. Anxiety/depression
3.3. Schizophrenia
3.4. Implications of 5-HT6 interactions and cognition
4. Conclusion
Acknowledgements
References

Corresponding Author Contact InformationCorresponding author. Tel.: 206 341 5803; fax: 206 341 5804.

Pharmacology & Therapeutics
Volume 108, Issue 3, December 2005, Pages 320-333
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.